SCHEMBL6492249

SCHEMBL6492249

Cc1cccc(C)c1C(=O)n1c(C)cc2cc(NC(=O)C3CCC(=O)C3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.48
PARP15 Q460N3 1/20 0.48
PARP10 Q53GL7 1/20 0.48
HSD17B10 Q99714 1/20 0.39
LMNA P02545 1/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.38
EPHX2 P34913 1/20 0.38
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
GNRHR P30968 1/20 0.36
GHSR Q92847 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494500 0.89 PARP1 (0.45) PARP1PARP15PARP10LMNAPOLB
SCHEMBL6489189 0.89 HSD17B10 (0.46) HSD17B10LMNAUBE2MDCUN1D1POLB
SCHEMBL6493472 0.87 PARP1 (0.44) PARP1PARP15PARP10HSD17B10POLB
SCHEMBL6490780 0.87 NPSR1 (0.48) HSD17B10LMNAUBE2MDCUN1D1POLB
SCHEMBL6480181 0.87 NPSR1 (0.51) HSD17B10LMNAUBE2MDCUN1D1POLB
SCHEMBL6480935 0.86 NPSR1 (0.50) HSD17B10LMNAALDH1A1NPSR1SMN1; SMN2
SCHEMBL6480758 0.85 PARP1 (0.42) PARP1PARP15PARP10HSD17B10LMNA
SCHEMBL6480301 0.83 PARP1 (0.44) PARP1PARP15PARP10UBE2MDCUN1D1
SCHEMBL6487994 0.79 MEN1 (0.46) LMNAUBE2MDCUN1D1MAPTNPSR1
SCHEMBL6489116 0.79 HSD17B10 (0.44) HSD17B10LMNAMAPTNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 PARP1 3678/4885PARP15 2460/4885PARP10 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.